Evidence map›Paper›PMID 41244891›Full record

ArticleInternational journal of nanomedicine2025

Near-Infrared Light-Responsive Copper Selenide Nanoparticle-Loaded Calcium Silicate Cement Induces Immunogenic Cell Death in Osteosarcoma.

Ruitang Liu, Ruilong Sun, Yun Xue, Yigui Zhou, Longwen Zhan, Yunfei Li, Yongzheng Tian, Chunyang Wang, Weike Feng, Bin Chang and 2 more

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ruitang Liu *Orthopedic Center, The 940th Hospital of the Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, People's Republic of China.ORCID 0009-0008-2112-6688
Ruilong Sun *Orthopedic Center, The 940th Hospital of the Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, People's Republic of China.
Yun Xue *Orthopedic Center, The 940th Hospital of the Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, People's Republic of China.
Yigui ZhouOrthopedic Center, The 940th Hospital of the Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, People's Republic of China.
Longwen ZhanOrthopedic Center, The 940th Hospital of the Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, People's Republic of China.
Yunfei LiOrthopedic Center, The 940th Hospital of the Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, People's Republic of China.
Yongzheng TianOrthopedic Center, The 940th Hospital of the Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, People's Republic of China.
Chunyang WangOrthopedic Center, The 940th Hospital of the Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, People's Republic of China.
Weike FengOrthopedic Center, The 940th Hospital of the Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, People's Republic of China.
Bin ChangOrthopedic Center, The 940th Hospital of the Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, People's Republic of China.
Bo FanOrthopedic Center, The 940th Hospital of the Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, People's Republic of China.ORCID 0009-0000-3453-3014
Qiuming GaoOrthopedic Center, The 940th Hospital of the Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Osteosarcoma is a highly malignant tumor posing significant treatment challenges, including limited efficacy of conventional therapies and difficulties in bone defect repair following resection. Although calcium silicate cement (CS) exhibits favorable characteristics as a bone filler, such as moldability and high compressive strength, its inherent lack of antitumor properties restricts its use in oncological contexts. Methods: A multifunctional composite bone cement was developed by incorporating nano-Cu2-xSe-a photothermal agent synthesized via a one-pot method-into a CS matrix. The material was systematically evaluated in terms of photothermal performance, setting time, compressive strength, and antitumor efficacy through in vitro assays and in vivo experiments using animal models. Mechanistic studies were conducted to assess whether immunogenic cell death (ICD) was induced in tumor cells. Results: The addition of only 0.2 wt% nano-Cu Discussion: This composite cement constitutes a dual-functional system capable of supporting bone defect repair while providing a photothermal antitumor effect, with potential immunogenic properties. The combination of improved material properties and efficient PTT performance highlights its promise as a strategy for treating bone tumors in a preclinical setting. These results support further development of this material for future translational studies in bone tissue engineering and oncology.

Indexed as

Bone CementsBone NeoplasmsCalcium CompoundsCopperImmunogenic Cell DeathNanoparticlesOsteosarcomaSilicatesAnimalsCell Line, TumorCompressive StrengthHumansInfrared RaysMicePhotothermal TherapyBone CementsCalcium Compoundscalcium silicateCopperSilicatescalcium silicateimmunogenic cell deathnano particleosteosarcomaphotothermal therapy

Identifiers

PMID41244891
PMCPMC12619626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.